INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Thomas John Charles sold KRYS

EVP, General Counsel · Krystal Biotech, Inc. · Common Stock

Side
SELL
Value
$194K
Shares
642
Price
$302.03
Executed
May 26, 2026
Disclosed
May 27, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
May 26 executedMay 27, 2026 disclosed

KRYS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+16 / 25

    $194K reported value · 100.0% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · KRYS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    MC
    Mason ChristopherDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    471 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SR
    Sutherland Everett RandDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    1,187 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Mason ChristopherDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    1,187 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SR
    Sutherland Everett RandDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    471 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Mazzacco CatherineDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    1,187 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Mazzacco CatherineDirector
    KRYSKrystal Biotech, Inc.
    Grant or award
    		A—
    471 sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    19
    TC
    Thomas John CharlesEVP, General Counsel
    KRYSKrystal Biotech, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$347K
    1,000 sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    0
    TC
    Thomas John CharlesEVP, General Counsel
    KRYSKrystal Biotech, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,000 sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    0
    TC
    Thomas John CharlesEVP, General Counsel
    KRYSKrystal Biotech, Inc.
    Option exercise · 10b5-1 plan
    		M$179K
    1,000 sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002114900-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 26, 2026
    Published
    May 27, 2026
    Ingested by INSIDER
    Nov 5, 03:56 UTC
    Last re-read
    Nov 5, 03:56 UTC

    Extracted facts

    Filer
    Thomas John Charles
    Role
    EVP, General Counsel
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Krystal Biotech, Inc.
    Ticker
    KRYS
    Shares
    642
    Price per share
    $302.03
    Value
    $193,903
    Execution date (reported)
    May 26, 2026
    Owned after transaction
    0 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 642
    • Price: $302.03

    = $193,903

    What this establishes

    Thomas John Charles filed this Form 4 reporting a open-market sale of KRYS on May 26, 2026. It became public on May 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, General Counsel
    Thomas John Charlescik:0002114900
    Issuer
    Krystal Biotech, Inc.cik:0001711279

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.